144 related articles for article (PubMed ID: 36734062)
21. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.
Najafi S; Tan SC; Aghamiri S; Raee P; Ebrahimi Z; Jahromi ZK; Rahmati Y; Sadri Nahand J; Piroozmand A; Jajarmi V; Mirzaei H
Biomed Pharmacother; 2022 Apr; 148():112743. PubMed ID: 35228065
[TBL] [Abstract][Full Text] [Related]
24. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
25. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing.
Duan L; Ouyang K; Xu X; Xu L; Wen C; Zhou X; Qin Z; Xu Z; Sun W; Liang Y
Front Genet; 2021; 12():673286. PubMed ID: 34054927
[TBL] [Abstract][Full Text] [Related]
27. [Application of nanoparticles in CRISPR/Cas9-based gene therapy].
Ma Y; Deng L; Li S
Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2087-2104. PubMed ID: 35786464
[TBL] [Abstract][Full Text] [Related]
28. Biomimetic Mineralized CRISPR/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing.
Liang Y; Zhang J; Xu C; Wang J; Han W; Yang J; Wu S; An J; Liu J; Zhang Z; Shi J; Zhang K
ACS Nano; 2023 Aug; 17(15):15025-15043. PubMed ID: 37481734
[TBL] [Abstract][Full Text] [Related]
29. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
Ma T; Chen X; Wang M
Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Evaluation of pH-Sensitive Multifunctional Lipids for Efficient Delivery of CRISPR/Cas9 in Gene Editing.
Sun D; Sun Z; Jiang H; Vaidya AM; Xin R; Ayat NR; Schilb AL; Qiao PL; Han Z; Naderi A; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):667-678. PubMed ID: 30582790
[TBL] [Abstract][Full Text] [Related]
32. Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment.
Wei Y; Zhao Z; Ma X
Front Immunol; 2022; 13():1037124. PubMed ID: 36479105
[TBL] [Abstract][Full Text] [Related]
33. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
34. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
[TBL] [Abstract][Full Text] [Related]
35. Special Focus Issue Part II: Recruitment of solid lipid nanoparticles for the delivery of CRISPR/Cas9: primary evaluation of anticancer gene editing.
Akbaba H; Erel-Akbaba G; Senturk S
Nanomedicine (Lond); 2021 May; 16(12):963-978. PubMed ID: 33970666
[No Abstract] [Full Text] [Related]
36. Nanoscale delivery of phytochemicals targeting CRISPR/Cas9 for cancer therapy.
Hussain Y; Khan H; Ahmad I; Efferth T; Alam W
Phytomedicine; 2022 Jan; 94():153830. PubMed ID: 34775359
[TBL] [Abstract][Full Text] [Related]
37. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
38. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
[TBL] [Abstract][Full Text] [Related]
39. Progress of delivery methods for CRISPR-Cas9.
Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
[TBL] [Abstract][Full Text] [Related]
40. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
Jubair L; Fallaha S; McMillan NAJ
Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
